I-Mab’s pipeline pivot had a sting in the tail. Weeks after shifting its focus, the biotech said Wednesday that it has reduced its workforce by around 27% in conjunction with the pipeline reprioritization.
https://www.fiercebiotech.com/biotech/i-mab-lays-27-workforce-after-pivoting-cldn182-bispecific